- Enhanced Recovery after Surgery (Eras) and Immunonutrition: An Evidence-based Approach
- Redhill Biopharma Extends Talicia® Unrestricted National and Regional Commercial Coverage to over 40 Million Additional Americans
- Fujifilm Earns Fda “breakthrough Device” Designation for Endosurgical Image Enhancement Technology
- Cognitive Deficit and White Matter Changes in Celiac Disease
- Family History of Colorectal Cancer and Prevalence of Advanced Colorectal Neoplasia in Screening
- Enhanced Recovery after Surgery (Eras) and Immunonutrition: An Evidence-based Approach
- Redhill Biopharma Extends Talicia® Unrestricted National and Regional Commercial Coverage to over 40 Million Additional Americans
- Fujifilm Earns Fda “breakthrough Device” Designation for Endosurgical Image Enhancement Technology
- Cognitive Deficit and White Matter Changes in Celiac Disease
- Family History of Colorectal Cancer and Prevalence of Advanced Colorectal Neoplasia in Screening
- Enhanced Recovery after Surgery (Eras) and Immunonutrition: An Evidence-based Approach
- Redhill Biopharma Extends Talicia® Unrestricted National and Regional Commercial Coverage to over 40 Million Additional Americans
- Fujifilm Earns Fda “breakthrough Device” Designation for Endosurgical Image Enhancement Technology
- Cognitive Deficit and White Matter Changes in Celiac Disease
- Family History of Colorectal Cancer and Prevalence of Advanced Colorectal Neoplasia in Screening

- This event has passed.
13th Annual Conference of the International Liver Cancer Association (ILCA)
September 20, 2019 - September 22, 2019
This 3-day cutting-edge international multidisciplinary forum will provide liver cancer specialists, clinical, translational and basic researchers and allied health professionals with updates in the latest innovations in liver cancer research and patient care.
Format: general sessions, symposia, workshops, Young Investigator session, industry partner lunch symposiums, workshop for nurses, and networking sessions.
~ 800 participants